LOS ANGELES, CA--(Marketwired - Jun 1, 2017) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease.
The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
"We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs," commented Endonovo CEO, Alan Collier.
, a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease. The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
"We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs," commented Endonovo CEO, Alan Collier.
1
